1. Outpatient administration of naxitamab in combination with granulocyte‐macrophage colony‐stimulating factor in patients with refractory and/or relapsed high‐risk neuroblastoma: Management of adverse events. Issue 1 (17th May 2022) Authors: Mora, Jaume; Chan, Godfrey C.; Morgenstern, Daniel A.; Nysom, Karsten; Bear, Melissa K.; Tornøe, Karen; Kushner, Brian H. Journal: Cancer reports Issue: Volume 6:Issue 1(2023) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗